Pregnancy-Related Systemic Lupus Erythematosus: Clinical Features, Outcome and Risk Factors of Disease Flares — A Case Control Study

• Published in: PloS one Vol. 9; no. 8; p. e104375
• Main Authors: Yang, Huaxia, Liu, Hui, Xu, Dong, Zhao, Lidan, Wang, Qian, Leng, Xiaomei, Zheng, Wenjie, Zhang, Fengchun, Tang, Fulin, Zhang, Xuan
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 13.08.2014; Public Library of Science (PLoS)
• Subjects: Adult; Anti-DNA antibodies; Autoimmune diseases; Biology and Life Sciences; Case-Control Studies; Chronic conditions; Comparative analysis; Complications; Demographics; Disease control; Eclampsia; Female; Fetal Death; Fetuses; Flares; Glucocorticoids; Health risks; Hematology; Humans; Hypocomplementemia; Incidence; Infection control; Logistic Models; Lupus; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - diagnosis; Medical prognosis; Medical research; Medicine and Health Sciences; Patients; Pre-eclampsia; Pre-Eclampsia - epidemiology; Pregnancy; Pregnancy complications; Pregnancy Complications - diagnosis; Pregnant women; Premature birth; Premature Birth - epidemiology; Prognosis; Puerperium; Risk analysis; Risk assessment; Risk Factors; Socioeconomic factors; Systemic lupus erythematosus; Womens health; Beijing China; United States > US; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0104375

To investigate the clinical features, outcome, and risk factors of disease flares in patients with pregnancy-related lupus (PRL). Medical charts of 155 consecutive PRL inpatients were systematically reviewed, including demographic data, clinical features, laboratory findings, treatment, complications, and outcome. PRL cases were divided into active (a-PRL) (n = 82, 53.0%) and stable lupus (s-PRL) (n = 73, 47.0%). Compared with nonpregnant active female systemic lupus erythematosus (SLE) patients, a-PRL including new-onset lupus (n-PRL) and flare lupus (f-PRL) (n = 41 respectively), had a higher incidence of renal and hematological involvement but less mucocutaneous and musculoskeletal involvement (p<0.05). The incidence of preeclampsia/eclampsia, fetal loss, and preterm birth were significantly higher in a-PRL than in s-PRL (p<0.05). Despite receiving a more vigorous glucocorticoid treatment, a-PRL mothers had a poorer prognosis (p<0.001). Five (6.1%) of them died and 13 (15.9%) developed severe irreversible organ failure, whereas none of these events was observed in the s-PRL group. Multivariate logistic analysis indicated that a history of lupus flares and serological activity (hypocomplementemia and/or anti-dsDNA positivity) at the time of conception were associated with lupus flares in PRL mothers. SLE patients with a flare history and serological activity at the time of conception were at an increased risk of disease flares during pregnancy and puerperium. a-PRL patients were more prone to renal and hematological involvement, pregnancy complications, and a poorer prognosis despite more vigorous glucocorticoid treatment.